ZR-MTX for PIOL Phase II Trial

NCT06973811 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Primary Intraocular Lymphoma

Interventions

DRUG: Methotrexate
DRUG: Rituximab (R)
DRUG: Zanubrutinib
DRUG: Methotrexate (MTX)

Sponsor

Peking Union Medical College Hospital